Clinical Trials on Squamous Cell Carcinoma of the Skin in United Kingdom

Total 3220 results

Memorial Sloan Kettering Cancer Center
Celgene Corporation; National Comprehensive Cancer Network

Completed

Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)

HEAD & NECK Cancer

United States
University of Chicago
EMD Serono

Active, not recruiting

Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer

Head and Neck Cancer | Head and Neck Neoplasms | Squamous Cell Carcinoma of Head and Neck

United States
Eli Lilly and Company

Completed

A Phase 1 Study in Participants With Advanced Cancer

Carcinoma, Non-Small-Cell Lung | Advanced Cancer | Anal Squamous Cell Carcinoma | Squamous Cell Carcinoma | Carcinoma, Squamous Cell of Head and Neck | Lung Squamous Cell Carcinoma Stage IV

United States
University of Wisconsin, Madison
Nektar Therapeutics

Terminated

Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

United States
Boston University

Recruiting

5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer

Superficial Basal Cell Carcinoma | Squamous Cell Carcinoma in Situ

United States
H. Lee Moffitt Cancer Center and Research Institute
Boehringer Ingelheim

Recruiting

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Squamous Cell Carcinoma

United States
NanoCarrier Co., Ltd.

Completed

NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Carcinoma, Squamous Cell of Head and Neck

United States, Hungary, Romania, Bulgaria
University of Chicago
Novartis Pharmaceuticals

Terminated

Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck

Head and Neck Cancer

United States
PeriRx

Unknown

Developing an In-vitro Diagnostic Risk-Stratification Test for Oral Cancer

Oral Squamous Cell Carcinoma

United States
M.D. Anderson Cancer Center

Recruiting

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

United States
Incyte Corporation
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Head and Neck Cancer

Canada, Spain, Korea, Republic of, United States, Austria, Japan, United Kingdom, Taiwan, Italy, Hungary, Australia, Turkey, Poland, Portugal
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

Human Papillomavirus Infection | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage IVC Oropharyngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II Oropharyngeal... and other conditions

United States
Pathway Genomics

Terminated

Circulating Tumor DNA in Patients at High Risk for Lung Cancer

Lung Neoplasms | Lung Cancer | Adenocarcinoma of the Lung | Cancer of the Lung | Small Cell Carcinoma of the Lung | Non Small Cell Carcinoma of the Lung

United States
University of Maryland, Baltimore

Withdrawn

Dendritic Cell Vaccine for Head and Neck Cancer (Dendritic)

Squamous Cell Carcinoma of Head and Neck

United States
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma

United States, Germany, Australia
University of Washington
National Cancer Institute (NCI); AstraZeneca

Terminated

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Hypopharyngeal... and other conditions

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer

Pain | Dysphagia | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II Oropharyngeal Squamous Cell Carcinoma | Stage III Oropharyngeal Squamous Cell Carcinoma

United States
Ascendis Pharma Oncology Division A/S

Recruiting

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor | Locally Advanced Solid Tumor | Neoadjuvant Melanoma | Head and Neck Squamous Cell Carcinoma HNSCC | HPV-associated Cancers | Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)

United States, Australia, Spain, Netherlands, Korea, Republic of, Taiwan
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Metastatic... and other conditions

United States
University of Michigan Rogel Cancer Center

Completed

Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer

Head and Neck Squamous Cell Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

Cetuximab-induced Papulopustular (Acneiform) Rash Who Have | Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder

United States
Celldex Therapeutics
Bristol-Myers Squibb

Completed

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Ovarian Carcinoma-Enrollment Completed | Colorectal Cancer (CRC)-Enrollment Completed | Renal Cell Carcinoma (RCC) (Phase ll Only) | Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed

United States
University of Wisconsin, Madison
National Cancer Institute (NCI)

Recruiting

Pilot Study of Imatinib Cetuximab Combo for H & N Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Oral Cavity Squamous Cell Carcinoma | Stage I Lip and Oral Cavity Cancer AJCC v8 | Stage II Lip and Oral Cavity Cancer AJCC v8 | Buccal Mucosa Squamous Cell Carcinoma | Floor of Mouth Squamous Cell Carcinoma | Gingival Squamous Cell Carcinoma | Hard Palate Squamous Cell Carcinoma | Lip Squamous Cell... and other conditions

United States, Canada
Washington University School of Medicine
Pfizer; The Joseph Sanchez Foundation

Recruiting

Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

HPV-unrelated Head and Neck Squamous Cell Carcinoma

United States
West Virginia University
West Virginia Clinical and Translational Science Institute

Terminated

Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis

Cancer of Head and Neck

United States
Nykode Therapeutics ASA
Merck Sharp & Dohme LLC

Recruiting

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

HNSCC | HPV-Related Squamous Cell Carcinoma

France, Norway, Spain, United Kingdom, Hungary, Poland, Czechia, Germany
Inhibrx, Inc.

Recruiting

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
M.D. Anderson Cancer Center
Gilead Sciences

Suspended

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck | Head Neck

United States
David Travis Thomas

Completed

Randomized Study of Beet Root in Locally Advanced Squamous Cell Cancer of the Head and Neck

Mucositis

United States
National Cancer Institute (NCI)

Terminated

Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

Locally Recurrent Head and Neck Squamous Cell Carcinoma | Nasopharyngeal Squamous Cell Carcinoma | Sinonasal Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Recurrent Prostate Cancer | Fallopian Tube Cancer | Bone Metastases | Lung Metastases | Stage III Renal Cell Cancer | Liver Metastases | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Inflammatory Breast Cancer | Metastatic Transitional Cell Cancer of the... and other conditions

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

Head and Neck Neoplasms

United States, Australia, Austria, Belgium, Brazil, Canada, Colombia, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, Taiwan, Turkey, United Kingdom
Memorial Sloan Kettering Cancer Center

Completed

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
RTOG Foundation, Inc.
Merck Sharp & Dohme LLC

Recruiting

SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE)

Head and Neck Squamous Cell Carcinoma (HNSCC)

Canada, United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer

Head and Neck Cancer | Head and Neck Neoplasms | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Nasopharyngeal Carcinoma | Current Smoker | Head and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Hypopharyngeal Squamous Cell Carcinoma | Laryngeal Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma

United States
BeiGene

Recruiting

Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

China, Italy, Taiwan, Australia, Spain, Korea, Republic of, France, United Kingdom, Thailand, Canada, United States, Georgia, Singapore, Turkey
Sanofi
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

Squamous Cell Carcinoma of Head and Neck

Spain, Italy, United States, Chile, France, Argentina, Canada, Germany, Korea, Republic of, Netherlands, Taiwan
ALX Oncology Inc.
Merck Sharp & Dohme LLC

Recruiting

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States, Belgium, Spain, Australia
Head and Neck Cancer International Group

Completed

Ascertaining the Radiologic Prognostic Importance of Extranodal Extension on Imaging (iENE) in Head and Neck Cancer (EPIC-iENE DATA)

Head and Neck Squamous Cell Carcinoma | Extranodal Extension | Human Papilloma Virus Related Carcinoma

Switzerland, United Kingdom, United States, Germany, Australia, France, Spain, Denmark
National Cancer Institute (NCI)

Active, not recruiting

Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell Carcinoma

United States
GlaxoSmithKline
Merck Sharp & Dohme LLC

Terminated

Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-4)

Neoplasms, Head and Neck

United States, Argentina, Italy, Spain, Belgium, Denmark, Poland, Canada, Germany, Korea, Republic of, Ireland, Japan, United Kingdom, Romania, Hungary, Australia, France, Brazil, Sweden, Russian Federation
Icahn School of Medicine at Mount Sinai

Withdrawn

RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC

Human Papillomavirus (HPV) | Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Xencor, Inc.
ICON plc

Completed

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Nasopharyngeal Carcinoma | Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Thymic Carcinoma | Thymoma | Non-small Cell Lung Carcinoma | Mesothelioma | Squamous Cell Carcinoma of the Head and Neck | Cholangiocarcinoma | Breast Carcinoma | Fallopian Tube Carcinoma and other conditions

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010) (LEAP-10)

Head and Neck Squamous Cell Carcinoma

United States, Australia, Brazil, Canada, China, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
University of Michigan Rogel Cancer Center

Completed

Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer

Oropharyngeal Squamous Cell Cancer

United States

Clinical Trials on Squamous Cell Carcinoma of the Skin in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations